8-K filing — Valion Bio, Inc. (VBIO)
Filed: 2026-10-08 AccNo: 0001683168-26-007709 Size: 222 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Valion Bio Appoints Dean Zikria Interim CEO, Thomas Jensen As Board Chair
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced decisive changes to its executive leadership team and Board of Directors (the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
VBIO stock has given up its prior gain. Valion Bio shares were trading higher after the company announced the completion of formulation work under the company's ongoing program to develop a novel oral mucosal formulation of Entolimod with Shear Kershman Laboratories.
Valion Bio shares are trading higher after the company announced the completion of formulation work under the company's ongoing program to develop a novel oral mucosal formulation of Entolimod with Shear Kershman Laboratories.
Valion Bio Announces Completion Of Needle-Free Oral Formulation Of Radiation Injury Drug Entolimod With Shear Kershman Laboratories